Drug Profile
Research programme- pancreatic cancer therapeutics - Boehringer Ingelheim/ University of Texas M.D. Anderson Cancer Center
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; University of Texas M. D. Anderson Cancer Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Pancreatic-cancer in USA
- 02 Dec 2015 Boehringer Ingelheim and The University of Texas M.D. Anderson Cancer Center enter into a collaboration to develop therapies for Pancreatic cancer
- 02 Dec 2015 Early research in Pancreatic cancer in USA (unspecified route)